Find A Physician
Return to Hematology (Blood Disorders) Overview
More on Hematology (Blood Disorders)
Hospital News
Return to Hematology (Blood Disorders) Overview
More on Hematology (Blood Disorders)
- Latest Findings Presented at Second International Symposium on Pediatric Non-Hodgkin's Lymphoma
- Integrative Therapies Program for Children with Cancer at Morgan Stanley Children's Hospital of NewYork-Presbyterian Receives Gift Commitment from Origins Natural Resources
- Multiple Myeloma Oral Therapy REVLIMID Approved by FDA
- Blood Platelet Levels Significantly Increased with Eltrombopag, Global Study Shows
- Clinical Trial for a Novel Multiple Myeloma Vaccine Begins at New York Weill Cornell Medical Center
- Columbia Receives $3 Million Award From Pediatric Cancer Foundation for New Research Laboratory
- Dr. Andrew I. Schafer Appointed Head of Department of Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Dr. Selina Chen-Kiang Honored as Researcher of the Year by the Leukemia and Lymphoma Society
- Eltrombopag Studied In Idiopathic Thrombocytopenic Purpura (ITP)
- First Successful Embryo Biopsy for Sickle Cell Anemia
- Gleevec May Be Effective Against a Second Blood Disease, According to Study To Be Presented at Hematology Meeting
- Helping Parents Do the Right Thing: New Guidelines on Umbilical Cord Blood Banking
- New Anti-Leukemia Drug Significantly Improves Survival Even for Patients With Late-Stage Disease, Study Finds
- NewYork-Presbyterian/Weill Cornell Multiple Myeloma Program Begins Clinical Trial of Promising New Chemotherapy Cocktail with Revlimid
- NewYork-Presbyterian Hospital and Columbia University Medical Center Physicians-Scientists Present Latest Cancer Findings at American Society of Hematology Meeting
- NewYork-Presbyterian Hospital Oncologists, from Columbia, Weill Cornell, Co-Lead World's Largest Lymphoma Forum for Patients
- Novel Drug Boosts Platelet Production, Reversing Chronic Immune Thrombocytopenic Purpura (ITP)
- One of the Nation's Largest Portfolios of New Lymphoma Therapies Targets Diverse and Difficult Cancer
- Study Shows Component of Saliva Is Very Effective in Blocking AIDS Virus
- Two Novel Biologics Studied for Multiple Myeloma
- Weill Cornell Medical College Hematologist Receives Prestigious NIH MERIT Award
- Weill Cornell Medical College Wins $7.5 Million Grant From Leukemia Society To Study Multiple Myeloma
- Weill Cornell Physician-Scientists Present Latest Cancer and Blood Findings at American Society of Hematology (ASH) Meeting
- Weill Cornell Scientists Discover New Paradigm for Cell Survival and Cell Death
Research and Clinical Trials
Return to Hematology (Blood Disorders) Overview
More on Hematology (Blood Disorders)
Health Library
Return to Hematology (Blood Disorders) Overview
More on Hematology (Blood Disorders)
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Alpha Thalassemia
- Anemia of Folate Deficiency
- Anemia Overview
- Aplastic Anemia
- Beta Thalassemia (Cooley's Anemia)
- Bleeding / Clotting Disorders
- Blood Donations / Blood Banking
- Blood Facts
- Blood Transfusions
- Bone Marrow Transplantation
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Cutaneous T-Cell Lymphoma
- G6PD (Glucose-6-Phosphate Dehydrogenase) Deficiency
- Hematology
- Hemochromatosis
- Hemolytic Anemia
- Hemophilia
- Idiopathic Thrombocytopenic Purpura
- Iron-Deficiency Anemia
- Leukemia Overview
- Megaloblastic (Pernicious) Anemia
- Myeloma Bone Disease / Multiple Myeloma
- Polycythemia Vera
- Septicemia
- Sickle Cell Disease
- Thalassemias
- Thrombocythemia
- Thrombosis
Clinical Services
Hematology (Blood Disorders)
At NewYork-Presbyterian Hospital teams of specialists in hematology manage a wide range of congenital and acquired blood disorders, such as anemias, neutropenias, trombocytopenias and thrombocytosis, and coagulation disorders, through disease-specific programs and centers and access to the latest therapies. Bone marrow transplantation has opened new horizons for treatment and, through the work pioneered by the Hospital's physicians, is giving hope for a cure to patients with sickle cell disease as well as those with thalassemia.
The Hospital's Comprehensive Sickle Cell Center – one of just ten centers in the country supported by the National Institutes of Health – offers diagnosis and genetic counseling for families affected by this hereditary blood disease. Physicians at the Hospital screen patients for stroke and other potential complications of sickle cell disease and provide treatment for those at risk. In cooperation with St. Luke's/Roosevelt Harlem Hospital and Mount Sinai Hospital, the Center cares for over 1000 patients.
The Hospital's Thalassemia Program is the largest comprehensive care and psychosocial support center of its kind in nation; the Hospital's Comprehensive Hemophilia Center is the first in New York State to offer isotopic radiation synovectomy to treat those who suffer from recurrent bleeding in their joints.
The Division of Hematology and Medical Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center offers comprehensive diagnostic and treatment services for patients with blood diseases. Our Platelet Disorder Center is the national leader for care of immune thrombocytopenic purpura (ITP) – a skin rash resulting from bleeding into the skin – and attracts patients from all over the United States and Canada. Other special programs in the Division include the Center for Lymphoma and Myeloma for patients with lymphoma, Hodgkin's Disease, and multiple myeloma, as well as the Program in Leukemia for patients with acute and chronic leukemias, myelodysplastic and myeloproliferative syndromes, and bone marrow failure syndromes.
In combination with other specialties, the Division of Hematology and Medical Oncology provides even more special programs, such as the Comprehensive Hemophilia Center (with Department of Pediatrics), the Vascular Biology Center (with Divisions of Vascular Surgery, Interventional Radiology, Cardiology, Hypertension, and Diabetology).
Find a Physician
Hospital News
- Latest Findings Presented at Second International Symposium on Pediatric Non-Hodgkin's Lymphoma
- Integrative Therapies Program for Children with Cancer at Morgan Stanley Children's Hospital of NewYork-Presbyterian Receives Gift Commitment from Origins Natural Resources
- Multiple Myeloma Oral Therapy REVLIMID Approved by FDA More
